What was the per-share value used for the Imunon (IMNN) CMO’s stock grant?

The stock grant to Imunon’s Chief Medical Officer was recorded at $1.59 per share . This valuation applies to the 3,649 shares of common stock granted on July 31, 2026, which were issued as part of his base salary compensation instead of cash payment.

Imunon, Inc. (IMNN) CMO granted stock in lieu of cash pay

Q: Was the Imunon (IMNN) CMO’s Form 4 transaction a market purchase or a compensation grant?

The transaction was a compensation-related stock grant , not a market purchase. Footnote disclosure states the 3,649 shares of common stock were "granted in lieu of cash" for a portion of Douglas Vincent Faller’s base salary at a value of $1.59 per share .

Q: How does the Imunon (IMNN) Form 4 describe the nature of the CMO’s stock award?

The Form 4 describes the award as "Stock granted in lieu of cash for portion of base salary" . This means the 3,649 shares of common stock were issued to Chief Medical Officer Douglas Vincent Faller as a non-cash component of his regular compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Faller Douglas Vincent reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. Chief Medical Officer Douglas Vincent Faller received a grant of 3,649 shares of common stock on July 31, 2026, valued at $1.59 per share. The shares were granted in lieu of cash for a portion of his base salary, increasing his direct holdings to 29,935 shares.

Insider Trade Summary

Net Buyer: 3,649 shares

Net Buy 1 txn

Insider Faller Douglas Vincent

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock ^F1	3,649	$1.59	$6K

Holdings After Transaction: Common Stock — 29,935 shares (Direct)

Footnotes (1)

F1. Stock granted in lieu of cash for portion of base salary

Key Figures

Shares granted: 3,649 shares Grant value per share: $1.59 per share Shares owned after grant: 29,935 shares

3 metrics

Shares granted 3,649 shares Common stock granted to Chief Medical Officer on July 31, 2026

Grant value per share $1.59 per share Valuation used for the CMO’s stock grant

Shares owned after grant 29,935 shares Direct Imunon common stock holdings of the CMO following the transaction

Key Terms

Form 4, grant/award acquisition, in lieu of cash, Chief Medical Officer

4 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

in lieu of cash financial

"Stock granted in lieu of cash for portion of base salary"

Chief Medical Officer other

"officer_title": "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:11 PM Accepted by SEC EDGAR 08/04/2026 - 04:11 PM

FAQ

What insider stock transaction did Imunon (IMNN) report for its Chief Medical Officer?

Imunon reported that Chief Medical Officer Douglas Vincent Faller received a grant of 3,649 common shares on July 31, 2026. The award was part of his compensation package, issued in lieu of cash salary, and was valued at $1.59 per share for reporting purposes.

How many Imunon (IMNN) shares does the CMO hold after this Form 4 transaction?

Following the reported stock grant, Chief Medical Officer Douglas Vincent Faller directly holds 29,935 shares of Imunon common stock. This figure reflects his position after receiving 3,649 shares granted as part of his base salary compensation on July 31, 2026.

Was the Imunon (IMNN) CMO’s Form 4 transaction a market purchase or a compensation grant?

The transaction was a compensation-related stock grant, not a market purchase. Footnote disclosure states the 3,649 shares of common stock were "granted in lieu of cash" for a portion of Douglas Vincent Faller’s base salary at a value of $1.59 per share.

How does the Imunon (IMNN) Form 4 describe the nature of the CMO’s stock award?

The Form 4 describes the award as "Stock granted in lieu of cash for portion of base salary". This means the 3,649 shares of common stock were issued to Chief Medical Officer Douglas Vincent Faller as a non-cash component of his regular compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faller Douglas Vincent

(Last)

(First)

(Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE

NEW JERSEY

08648

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/31/2026		A		3,649⁽¹⁾	A	$1.59	29,935	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

	/s/ Susan Eylward, Attorney-in-Fact for Douglas Faller	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR